Flag of the European Union EU Clinical Trials Register Help

Clinical trials for (CP-690,550) Tofacitinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: (CP-690,550) Tofacitinib. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-005035-19 Sponsor Protocol Number: A3921024 Start Date*: 2007-04-17
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB (CP-690,550) FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) AT (Completed) SE (Completed) IT (Completed) HU (Completed) CZ (Completed) GR (Completed) DE (Completed) SK (Completed) GB (Completed) BG (Completed) FI (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002378-30 Sponsor Protocol Number: A3921210 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc.
    Full Title: OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Medical condition: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) SK (Completed) FR (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002169-39 Sponsor Protocol Number: A3921092 Start Date*: 2014-03-26
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS Paediatric investigation plan numbers - (P/144/2010),(P/162/2011) and (P/0064/2012).
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018188 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) CZ (Completed) BG (Completed) SK (Completed) PL (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001733-16 Sponsor Protocol Number: A3921083 Start Date*: 2012-04-10
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE C...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) ES (Completed) HU (Completed) GR (Completed) AT (Completed) CZ (Completed) NL (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004581-14 Sponsor Protocol Number: A3921139 Start Date*: 2012-06-29
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) HU (Completed) EE (Completed) GB (Completed) LV (Completed) BE (Completed) NL (Completed) ES (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004579-35 Sponsor Protocol Number: A3921095 Start Date*: 2012-05-01
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Moderate to severe active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) EE (Completed) DK (Completed) LV (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003668-55 Sponsor Protocol Number: A3921091 Start Date*: 2013-11-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paedi...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001754-28 Sponsor Protocol Number: A3921084 Start Date*: 2012-06-05
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE C...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) HU (Completed) ES (Completed) AT (Completed) NL (Completed) CZ (Completed) GR (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004580-79 Sponsor Protocol Number: A3921096 Start Date*: 2012-02-24
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) HU (Completed) EE (Completed) GB (Completed) LV (Completed) BE (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) IT (Completed) SK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004578-27 Sponsor Protocol Number: A3921094 Start Date*: 2012-04-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) HU (Completed) EE (Completed) LV (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) SK (Completed) PL (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020002-15 Sponsor Protocol Number: A3921061 Start Date*: 2010-11-15
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Medical condition: Moderate To Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Completed) NL (Completed) FI (Prematurely Ended) ES (Completed) DK (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) AT (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002274-39 Sponsor Protocol Number: A3921288 Start Date*: 2017-12-08
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) HU (Completed) NL (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003622-27 Sponsor Protocol Number: A3921086 Start Date*: 2012-06-07
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Completed) HU (Completed) DE (Completed) CZ (Completed) BG (Completed) GR (Completed) NL (Completed) AT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020005-32 Sponsor Protocol Number: A3921111 Start Date*: 2011-02-08
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVE...
    Medical condition: Chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000903-41 Sponsor Protocol Number: A3921053 Start Date*: 2011-10-24
    Sponsor Name:Pfizer, S.L.U.
    Full Title: AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES
    Medical condition: KIDNEY TRANSPLANT
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002345-23 Sponsor Protocol Number: A3921050 Start Date*: 2008-11-28
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA
    Full Title: A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS
    Medical condition: Prevention of kidney allograft rejection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10066543 Acute allograft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed) BE (Completed) NL (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-001368-46 Sponsor Protocol Number: A3921125 Start Date*: 2013-10-23
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONS...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004915-22 Sponsor Protocol Number: A3921145 Start Date*: 2012-08-03
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Trial now transitioned) DE (Completed) SK (Completed) IT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001438-46 Sponsor Protocol Number: A3921104 Start Date*: 2018-03-27
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020004-30 Sponsor Protocol Number: A3921080 Start Date*: 2010-10-05
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS ...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) SK (Completed) BG (Completed) AT (Completed) PT (Completed) BE (Completed) DK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:59:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA